The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The analysis, led by Adam D. Cohen, MD, of University of Pennsylvania in Philadelphia, reviewed 20 patients from Cohort A of the CARTITUDE-2 trial that rolled over to the 15-year follow-up study, CARTinue.
The study’s authors, led by Marin Schrappe, MD, of Christian Albrechts University Kiel and University Hospital Schleswig-Holstein in Germany, enrolled pediatric patients with high-risk B-ALL to receive two cycles of either blinatumomab or control chemotherapy after consolidation therapy. The primary end point was EFS based on a time-to-event analysis.
Drs. Phillip Scheinberg, Imre Bodó and Ciprian Tomuleasa on the inaugural SOHO CE meeting, which was held in Budapest in October 2026.
Hagop Kantarjian, MD, tells the story of the founding of the Society of Hematologic Oncology and the society’s mission in developing young investigators and disseminating knowledge worldwide.
In the first part of a two-video series, Guillermo Garcia-Manero, MD, discusses the treatment of lower-risk myelodysplastic syndromes (MDS) with SOHO young investigators during SOHO 2026.
Host Dr. Loretta Nastoupil discusses with Dr. Lee the operational, structural, and financial barriers to trial accrual, as well as practical approaches to bring complex studies, including bispecific antibodies and early-phase regimens, into community oncology settings. Watch more from the Community Oncology series.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
